ADX-2191 — Clinical data readout
2026
Phase 3 clinical trial initiation expected H1 2026; results expected in 2026Source filing
ALDX biotech catalysts & pipeline
ALDEYRA THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
ADX-246 — IND submission
2026
Investigational New Drug application expected to be submitted in 2026Source filing
ADX-248 — IND submission
2026
Investigational New Drug application expected to be submitted in 2026Source filing
reproxalap — FDA meeting
Q4 2026
Based on established timelines for FDRR, Aldeyra expects to meet with OND in the fourth quarter of 2026.Source filing